Polycythemia Vera Interferon Therapeutics Market

Interferons Market Analysis

The Interferons Market size is estimated at USD 10.55 billion in 2025, and is expected to reach USD 12.78 billion by 2030, at a CAGR of 3.91% during the forecast period (2025-2030).

The increasing prevalence of diseases such as hepatitis, multiple sclerosis, and cancers and the high target affinity and specificity of interferons are actively affecting the growth of the market.

Interferons, particularly interferon alpha, have been a cornerstone in the treatment of chronic hepatitis B and C. Although direct-acting antivirals (DAAs) have largely supplanted interferons for hepatitis C, interferons remain an option, especially in certain clinical situations or where DAAs are unavailable. The ongoing need for hepatitis management, particularly in regions with high prevalence rates, supports sustained demand for interferon-based treatments. For instance, according to data published by the World Health Organization in April 2024, around 254 million individuals globally were affected by chronic hepatitis B in 2022, witnessing 1.2 million new infections each year. The disease led to roughly 1.1 million fatalities in 2022, predominantly from cirrhosis and liver cancer. Thus, the high burden of hepatitis B is expected to increase demand for the treatment, with interferons contributing to the market growth.

Further, the high burden of multiple sclerosis (MS) is expected to create an opportunity for interferon beta development, propelling market growth. For instance, according to data published by the Multiple Sclerosis International Federation in 2024, the global prevalence of MS stood at an estimated 2.9 million in 2023, marking an increase from 2.8 million in 2020. As the prevalence of MS continues to rise, there is a continued demand for effective disease-modifying therapies, including interferons, to manage the condition and improve patient outcomes is likely to propel the market growth.

Market players drive growth through strategic initiatives, including product launches, clinical developments, securing approvals, and forming partnerships. For instance, in August 2023, iX Biopharma Ltd unveiled its latest development program, IXB-322. This innovative wafer, containing a low dose of interferon alpha (≤ 1000 IU), is designed for sublingual delivery. Its primary aim is to prevent and treat respiratory viral illnesses, including COVID-19, influenza, and respiratory syncytial virus (“RSV”). This approach is being compared to treatment with PEG-IFNα alone. Thus, such trials lead to innovative launches to create more treatment options for MS market players, which are anticipated to propel market growth.

Therefore, owing to the aforementioned factors, such as the high prevalence of chronic diseases like hepatitis and cancer and product approvals, the market is anticipated to grow during the study period. However, the high research and development costs are likely to impede market growth.

Interferons Market Trends

The Leukemia Segment is Expected to Hold a Significant Market Share During the Forecast Period

Interferon alpha is often used in treating chronic myeloid leukemia (CML). The segment is expected to show stable growth during the forecast period due to the high burden of leukemia and rising product approvals and launches by market players.

According to the American Cancer Society (ACS) 2024 report, 1.0 million new cancer cases were diagnosed in the United States by the first half of 2024. Out of the reported new cancer cases, leukemia was reported with 62,770 new cases, and lymphoma with 89,190 new cases.

Additionally, the Leukemia Foundation's 2023 update reveals that in 2023, 19,400 Australians received a diagnosis of blood cancers, including leukemia, lymphoma, and myeloma. This was equivalent to 53 people daily or one person every 27 minutes. The same source stated that 135,000 individuals were living with blood cancer in Australia in 2023, and more than 275,000 Australians are expected to be living with blood cancer by 2035. Thus, the high burden of leukemia is expected to bolster the segment growth during the forecast period.

Additionally, ongoing research and development activities for interferon therapy in treating leukemia are expected to drive market innovation and growth during the forecast period. For instance, in February 2024, the University of Pittsburgh announced a Phase 2 interferon-γ (IFN-γ) trial in combination with donor leukocyte infusion (DLI). The trial targets relapsed acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) post-allogeneic hematopoietic stem cell transplantation (alloSCT). Based on the positive results of the previous Phase 1 trial, this Phase 2 study intends to strengthen its findings by gathering leukemia cells before and after in vivo IFN-γ therapy. Therefore, these ongoing clinical trials are anticipated to contribute to the growth of this field.

Therefore, owing to the high burden of leukemia, the company's research and development for developing an innovative product are anticipated to propel the segment's growth during the forecast period.

North America is Expected to Hold a Significant Market Share During the Forecast Period

North America is expected to hold a significant share of the interferons market due to the high burden of cancer coupled with developed medical and healthcare establishments and the launch of advanced products in the region.

The high burden of hepatitis in the region is expected to propel the growth of the market. For instance, as per Center for Disease Control and Prevention data updated in April 2024, the United States reported 13,300 new cases of hepatitis B in 2022, highlighting a significant public health concern that requires ongoing monitoring and intervention. Thus, the high burden of hepatitis B is expected to increase demand for the treatment, with interferons contributing to the market growth.

Interferon alpha treats several cancers, including malignant melanoma and renal cell carcinoma. It boosts the immune system's capacity to identify and eliminate cancer cells. With cancer incidence rates increasing globally, the need for effective treatment options, including interferons, drives market demand. For instance, according to the American Cancer Society 2024, 81,610 new kidney and renal pelvis cases were diagnosed in the United States. Most kidney cancers are renal cell carcinomas. Hence, the high burden of renal cell carcinoma is anticipated to propel the market growth during the forecast period.

Moreover, the growth of the market in North America is fueled by the presence of key players, increasing awareness initiatives, and the launch of innovative products in the region. Moreover, in May 2024, CytomX Therapeutics Inc. and Merck (called MSD outside the United States and Canada) entered a collaboration and supply agreement for a clinical trial. This trial is CytomX's first-in-human Phase 1 study, evaluating the clinical efficacy of CX-801. CX-801 is a dually-masked interferon alpha2b cytokine, being tested in conjunction with Merck's renowned anti-PD-1 therapy, KEYTRUDA (pembrolizumab). Interferon alpha-2 b is a potent cytokine recognized for its clinical efficacy against various cancer types. Thus, such developments for interferons in the region are expected to boost the growth of the market during the forecast period.

Thus, the high burden of hepatitis, renal cell carcinoma, and strategic activities by the market players are expected to boost the market in North America during the forecast period.

Interferons Industry Overview

The interferons market is semi-consolidated and consists of local and global players. The market players are engaged in research and development and strategic activities such as product launches and mergers and acquisitions to gain the majority share in the market. Some companies dominating the market are Merck & Co. Inc., Biogen Inc., Bayer AG, Amega Biotech, and F. Hoffmann-La Roche Ltd.

Interferons Market Leaders

Interferons Market News

• August 2024: Pharmaand GmbH (pharma&) announced that the European Commission (EC) granted marketing authorization for a Type II variation of Pegasys (peginterferon alfa-2a). This authorization allows Pegasys to be used as a monotherapy treatment for adults diagnosed with polycythemia vera (PV) or essential thrombocythemia (ET).
• September 2023: Eiger Biopharmaceuticals Inc. provided an update on the status of its planned request for emergency use authorization (EUA) of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19. This update was based on the most recent communications with the US Food and Drug Administration.